Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Cervarix two-dose schedule receives European marketing authorization

Dec. 24, 2013

Regulatory application filed for nivolumab in malignant melanoma

Dec. 24, 2013

California Stem Cell completes phase I stem cell trial for HCC

Dec. 23, 2013

Roche to study RO-6895882 in advanced and/or metastatic solid tumors

Dec. 23, 2013

GSK and Genmab receive FDA priority review for Arzerra BLA

Dec. 19, 2013

Chimeric antigen receptor therapy for pediatric ALL targets the TSLPR

Dec. 18, 2013

arGEN-X reports findings from dose-escalation part of phase Ib study of ARGX-110

Dec. 18, 2013

Researchers from the University of California present two novel ROR1-targeting therapies

Dec. 18, 2013

Final phase I lymphoma results presented for antibody-drug conjugates from Genentech

Dec. 17, 2013

KaloBios Pharmaceuticals presents phase I results for KB-004

Dec. 16, 2013

Popular Stories

University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Beijing Innocare Pharma Tech discloses new GSPT1 degradation inducers
BioWorld Science
Beijing Innocare Pharma Tech Co. Ltd. has synthesized new antibody-drug conjugates comprising antibody or antigen-binding fragment covalently linked to eukaryotic...